Anti-obesity activity of the marine carotenoid fucoxanthin

Marine Drugs

Volumn 13, Issue 4, 2015, Pages 2196-2214

  Gammone, Maria Alessandra ^a   D'Orazio, Nicolantonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Fucoxanthin; Functional food; Metabolism; Nutrition; Obesity

Indexed keywords

AMAROUCIAXANTHIN A; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CARBAMAZEPINE; CAROTENOID; CLOZAPINE; CYTOKINE; DOCOSAHEXAENOIC ACID; FUCOXANTHIN; FUCOXANTHINOL; GLUCOSE; LEPTIN; LITHIUM SALT; NEUROLEPTIC AGENT; OLANZAPINE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; VALPROIC ACID; ANTIOBESITY AGENT; ANTIOXIDANT; NONSTEROID ANTIINFLAMMATORY AGENT; XANTHOPHYLL;

ABDOMINAL FAT; ABDOMINAL OBESITY; ADIPOSE TISSUE CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; HEREDITY; HORMONAL REGULATION; HUMAN; INSULIN RESISTANCE; LETHARGY; LIPID METABOLISM; LIVER PROTECTION; LOW CALORY DIET; MACROPHAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIGENOMICS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THERAPY RESISTANCE; THERMOGENESIS; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; CHEMISTRY; DIATOM; DIET THERAPY; DIETARY SUPPLEMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; LAMINARIA; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; SEAWEED; STRAMENOPILE; UNDARIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-OBESITY AGENTS; ANTIOXIDANTS; DIATOMS; DIETARY SUPPLEMENTS; HUMANS; LAMINARIA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; SEAWEED; STRAMENOPILES; UNDARIA; XANTHOPHYLLS;

EID: 84928411843     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13042196     Document Type: Review

References (67)

1. Kuipers, R.S.; de Graaf, D.J.; Luxwolda, M.F.; Muskiet, M.H.; Dijck-Brouwer, D.A.; Muskiet, F.A. Saturated fat, carbohydrates and cardiovascular disease. Neth. J. Med. 2011, 69, 372-378.
2. Kim, S.M.; Jung, Y.H.; Kwon, O.; Cha, K.H.; Um, B.H. A potential commercial source of fucoxanthin extracted from the microalga Phaeodactylum tricornutum. Appl. Biochem. Biotechnol. 2012, 166, 1843-1855.
3. Maeda, H.; Hosokawa, M.; Sashima, T.; Miyashita, K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J. Agric. Food Chem. 2007, 55, 7701-7706.
4. Woo, M.N.; Jeon, S.M.; Kim, H.J.; Lee, M.K.; Shin, S.K.; Shin, Y.C.; Park, Y.B.; Choi, M.S. Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice. Chem. Biol. Interact. 2010, 186, 316-322.
5. Sangeetha, R.K.; Bhaskar, N.; Baskaran, V. Comparative effects of β-carotene and fucoxanthin on retinol deficiency induced oxidative stress in rats. Mol. Cell. Biochem. 2009, 331, 59-67.
6. Lee, S.J.; Bai, S.K.; Lee, K.S.; Namkoong, S.; Na, H.J.; Ha, K.S; Han, J.A.; Yim, S.V.; Chang, K.; Kwon, Y.G.; et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(κ)B kinase-dependent NF-κB activation. Mol. Cells 2003, 16, 97-105.
7. Kim, K.N.; Ahn, G.; Heo, S.J.; Kang, S.M.; Kang, M.C.; Yang, H.M.; Kim, D.; Roh, S.W.; Kim, S.K.; Jeon, B.T.; et al. Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16-F10 cells. Envir. Toxicol. Pharmacol. 2013, 35, 39-46.
8. McNulty, H.; Jacob, R.F.; Mason, R.P. Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am. J. Cardiol. 2008, 101, 20D-29D.
9. Seifried, H.E.; Anderson, D.E.; Fisher, E.I.; Milner, J.A. A review of the interaction among dietary antioxidants and reactive oxygen species. J. Nutr. Biochem. 2007, 18, 567-579.
10. Hu, T.; Liu, D.; Chen, Y.; Wu, J.; Wang, S. Antioxidant activity of sulfated polysaccharide fractions extracted from Undaria pinnitafida in vitro. Int. J. Biol. Macromol. 2010, 46, 193-198.
11. Sangeetha, R.K.; Bhaskar, N.; Divakar, S.; Baskaran, V. Bioavailability and metabolism of fucoxanthin in rats: Structural characterization of metabolites by LC-MS (APCI). Mol. Cell. Biochem. 2010, 333, 299-310.
12. Das, S.K.; Hashimoto, T.; Kanazawa, K. Growth inhibition of human hepatic carcinoma Hep-G2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim. Biophys. Acta 2008, 1780, 743-749.
13. Asai, A.; Sugawara, T.; Ono, H.; Nagao, A. Biotransformation of fucoxanthinol in amarouciaxanthin A in mice and Hep-G2 cells: Formation and cytotoxicity of fucoxanthin metabolites. Drug Metab. Dispos. 2004, 32, 205-211.
14. Hashimoto, T.; Ozaki, Y.; Taminato, M.; Das, S.K.; Mizuno, M.; Yoshimura, K.; Maoka, T.; Kanazawa, K. The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice. Br. J. Nutr. 2009, 102, 242-248.
15. Gammone, M.A.; Riccioni, G.; D'Orazio, N. Carotenoids: Potential allies of cardiovascular health? Food Nutr. Res. 2015, 59, 26762.
16. Asai, A.; Yonekura, L.; Nagao, A. Low bioavailability of dietary epoxy-xanthophylls in humans. Br. J. Nutr. 2008, 100, 273-277.
17. Hu, X.; Li, Y.; Li, C.; Fu, Y.; Cai, F.; Chen, Q.; Li, D. Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats. Arch. Biochem. Biophys. 2012, 519, 59-65.
18. Tong, L. Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell. Mol. Life Sci. 2005, 62, 1784-1803.
19. Beppu, F.; Hosokawa, M.; Niwano, Y.; Miyashita, K. Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-A(y) mice. Lipids Health Dis. 2012, 11, 112.
20. Wu, M.; Singh, S.B.; Wang, J.; Chung, C.C.; Salituro, G.; Karanam, B.V.; Lee, S.H.; Powles, M.; Ellsworth, K.P.; Lassman, M.E.; et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. USA 2011, 108, 5378-5383.
21. Beppu, F.; Hosokawa, M.; Yim, M.J.; Shinoda, T.; Miyashita, K. Down-regulation of hepatic stearoyl-CoA desaturase-1 expression by fucoxanthin via leptin signaling in diabetic/obese KK-A(y) mice. Lipids 2013, 48, 449-455.
22. th ed.; Saunders/Elsevier, Philadelphia, PA, USA, 2010; Volume 33, pp. 340-341.
23. Eberlé, D.; Hegarty, B.; Bossard, P.; Ferré, P.; Foufelle, F. SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie 2004, 86, 839-848.
24. Ferré, P.; Foufelle F. Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12, 83-92.
25. DeVries, R.; Borggreve, S.E.; Dullaart, R.P. Role of lipases, lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin. Lab. 2004, 49, 601-613.
26. Rasmussen, B.B.; Holmbäck, U.C.; Volpi, E.; Morio-Liondore, B.; Paddon-Jones, D.; Wolfe, R.R. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J. Clin. Invest. 2002, 110, 1687-1693.
27. Maeda, H.; Hosokawa, M.; Sashima, T.; Murakami-Funayama K.; Miyashita, K. Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditionsin a murine model. Mol. Med. Rep. 2009, 2, 897-902.
28. Kang, S.I.; Shin, H.S.; Kim, H.M.; Yoon, S.A.; Kang, S.W.; Kim, J.H.; Ko, H.C.; Kim, S.J. Petalonia binghamiae extract and its constituent fucoxanthin ameliorate high-fat diet-induced obesity by activating AMP-activated protein kinase. J. Agric. Food Chem. 2012, 60, 3389-3395.
29. Ntambi, J.M.; Kim, Y.C. Adipocyte differentiation and gene expression. J. Nutr. 2000, 12, 3122-3126.
30. Kang, S.I.; Ko, H.C.; Shin, H.S.; Kim, H.M.; Hong, Y.S.; Lee, N.H.; Kim, S.J. Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem. Biophys. Res. Commun. 2011, 409, 769-777.
31. Maeda, H.; Hosokawa, M.; Sashima, T.; Takahashi, N.; Kawada, T.; Miyashita, K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Intern. J. Mol. Med. 2006, 18, 147-152.
32. Yim, M.J.; Hosokawa, M.; Mizushina, Y.; Yoshida, H.; Saito, Y.; Miyashita, K. Suppressive effects of amarouciaxanthin A on 3T3-L1 adipocyte differentiation through down-regulation of PPAR-γ and C/EBPr mRNA expression. J. Agric. Food Chem. 2011, 59, 1646-1652.
33. D'Orazio, N.; Gemello, E.; Gammone, M.A.; DeGirolamo, M.; Ficoneri, C.; Riccioni, G. Fucoxantin: A treasure from the sea. Mar. Drugs 2012, 10, 604-616.
34. Gammone, M.A.; Gemello, E.; Riccioni, G.; D'Orazio, N. Marine bioactives and potential application in sports. Mar. Drugs 2014, 12, 2357-2382.
35. Maeda, H.; Hosokawa, M.; Sashima, T.; Funayama, K.; Miyashita, K. Fucoxanthin from edible seaweed Undaria pinnatifida, shows anti-obesity effect through UCP1 expression in white adipose tissues. Biochem. Biophys. Res. Commun. 2005, 332, 392-397.
36. Abidov, M.; Ramazanov, Z.; Seifulla, R.; Grachev, S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabet. Obes. Metable 2010, 12, 72-81.
37. Heilbronn, L.K.; Noakes, M.; Clifton, M.P. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Atheroscler. Thromb. Vasc. Biol. 2001, 21, 968-970.
38. Hosokawa, M.; Miyashita, T.; Nishikawa, S.; Emi, S.; Tsukui, T.; Beppu, F.; Okada, T.; Miyashita, K. Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-Ay mice. Arch. Biochem. Biophys. 2010, 504, 17-25.
39. Gautron, L.; Elmquist, J.K. Sixteen years and counting: An update on leptin in energy balance. J. Clin. Invest. 2011, 121, 2087-2093.
40. Roujeau, C.; Jockers, R.; Dam, J. New pharmacological perspectives for the leptin receptor in the treatment of obesity. Front Endocrinol. 2014, 13, 5-167.
41. Park, H.J.; Lee, M.K.; Park, Y.B.; Shin, Y.C.; Choi, M.S. Beneficial effects of Undaria pinnatifida ethanol extract on diet-induced-insulin resistance in C57BL/6J mice. Food Chem. Toxicol. 2011, 49, 727-733.
42. Tsujino, N.; Sakurai T. Circadian rhythm of leptin, orexin and ghrelin. Nihon Rinsho 2012, 70, 1121-1125.
43. Sakurai, T. Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Neurol. Disord. Drug Targets 2006, 5, 313-325.
44. Blundell, J.E.; Gibbons, C.; Caudwell, P.; Finlayson, G.; Hopkins, M. Appetite control and energy balance: Impact of exercise. Obes. Rev. 2015, 16, 67-76.
45. Maeda, H.; Tsukui, T.; Sashima, T.; Hosokawa, M.; Miyashita, K. Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient. Asia Pac. J. Clin. Nutr. 2008, 17, 196-199.
46. Tsukui, T.; Konno, K.; Hosokawa, M.; Maeda, H.; Sashima, T.; Miyashita, K. Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in the liver of KKAy obese/diabetic mice. J. Agric. Food Chem. 2007, 55, 5025-5029.
47. Tsukui, T.; Baba, T.; Hosokawa, M.; Sashima, T.; Miyashita, K. Enhancement of hepatic docosahexaenoic acid and arachidonic acid contents in C57BL/6J mice by dietary fucoxanthin. Fish. Sci. 2009, 75, 261-263.
48. Airanthi, M.K.W.A.; Sasaki, N.; Iwasaki, S.; Baba, N.; Abe, M.; Hosokawa, M.; Miyashita, K. Effect of brown seaweed lipids on fatty acid composition and lipid hydroperoxide levels of mouse liver. J. Agric. Food Chem. 2011, 59, 4156-4163.
49. Masterton, G.S.; Plevris, J.N.; Hayes, P.C. Review article: Omega-3 fatty acids-A promising novel therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2010, 31, 679-692.
50. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111, 1448-1454.
51. D'Orazio, N.; Gammone, M.A.; Gemello, E., DeGirolamo, M.; Cusenza, S.; Riccioni, G. Marine bioactives: Pharmacological properties and potential applications against inflammatory diseases. Mar. Drugs 2012, 10, 812-833.
52. Ha, A.W.; Na, S.J.; Kim, W.K. Antioxidant effects of fucoxanthin rich powder in rats fed with high fat diet. Nutr. Res. Pract. 2013, 7, 475-480.
53. Liu, C.L.; Chiu, Y.T.; Hu, M.L. Fucoxanthin enhances HO-1 and NQO1 expression in murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system partially by its pro-oxidant activity. J. Agric. Food Chem. 2011, 59, 11344-11351.
54. Orton, R.J.; Sturm, O.E.; Vyshemirsky, V.; Calder, M.; Gilbert, D.R.; Kolch, W. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem. J. 2005, 392, 249-261.
55. Kim, K.N.; Heo, S.J.; Kang, S.M.; Ahn, G.; Jeon, Y.J. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol. Vitro 2010, 24, 1648-1654.
56. Kim, K.N.; Heo, S.J.; Yoon, W.J.; Kang, S.M.; Ahn, G.; Yi, T.H.; Jeon, Y.J. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur. J. Pharmacol. 2010, 649, 369-375.
57. Sakai, S.; Sugawara, T.; Matsubara, K.; Hirata, T. Inhibitory effect of carotenoids on the degranulation of mast cells via suppression of antigen-induced aggregation of high affinity IgE receptor. J. Biol. Chem. 2009, 284, 28172-28179.
58. Brondani, L.A.; Assmann, T.S.; Duarte, G.C.; Gross, J.L.; Canani, L.H.; Crispim, D. The role of the uncoupling protein 1 (UCP1) on the development of obesity and type 2 diabetes mellitus. Arq Bras. Endocrinol. Metabol. 2012, 56, 215-225.
59. Jia, J.J.; Tian, Y.B.; Cao, Z.H.; Tao, L.L.; Zhang, X.; Gao, S.Z. The polymorphisms of UCP1 genes associated with fat metabolism, obesity and diabetes. Mol. Biol. Rep. 2010, 37, 1513-1522.
60. Clément, K.; Ruiz, J.; Cassard-Doulcier, A.M.; Bouillaud, F.; Ricquier, D.; Basdevant, A.; Guy-Grand, B.; Froguel, P. Additive effect of A→G (-3826) variant of the uncoupling protein gene and the Trp64Arg mutation of the β3-adrenergic receptor gene on weight gain in morbid obesity. Int. J. Obes. Relat. Metab. Disord . 1996, 20, 1062-1066.
61. Fogelholm, M.; Valve, R.; Kukkonen-Harjula, K.; Nenonen, A.; Hakkarainen, V.; Laakso, M. Additive effects of the mutations in the β3-adrenergic receptor and uncoupling protein-1 genes on weight loss and weight maintenance in Finnish women. J. Clin. Endocrinol. Metab. 1998, 83, 4246-4250.
62. Schäffler, A.; Palitzsch, K.D.; Watzlawek, E.; Drobnik, W.; Schwer, H.; Schölmerich, J. Frequency and significance of the A→G (-3826) polymorphism in the promoter of the gene for uncoupling protein-1 with regard to metabolic parameters and adipocyte transcription factor binding in a large population-based Caucasian cohort. Eur. J. Clin. Invest. 1999, 29, 770-779.
63. Lu, M.; Wang, T.; Lin, T.; Shao, W.; Chang, S.; Chou, J.; Ho, Y.; Liao, Y.; Chen, V.C. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 9, 47-50.
64. Domecq, J.P.; Prutsky, G.; Leppin, A.; Sonbol, M.B.; Altayar, O.; Undavalli, C.; Wang, Z.; Elraiyah, T.; Brito, J.P.; Mauck, K.F.; et al. Drugs commonly associated with weight change: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2015, 15, 1-8.
65. Lamp, Y.; Eshel, Y.; Rapaport, A.; Sarova-Pinhas, I. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin. Neuropharmacol. 1991, 14, 251-255.
66. Shen, J.; Obin, M.S.; Zhao, L. The gut microbiota, obesity and insulin resistance. Mol. Aspects Med. 2013, 34, 39-58.
67. Stachowicz, N.; Kiersztan, A. The role of gut microbiota in the pathogenesis of obesity and diabetes. Postepy Hig. Med. Dosw. 2013, 67, 288-303.